Emestedastat

N/A

Report date: 2026/02/18 20:02:09
NME

Base Information

Drug NameEmestedastat
Drug Alias NameXanamemUE-2343
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCorticosteroid 11-beta-dehydrogenase isozyme 1 inhibitors
TargetsCorticosteroid 11-beta-dehydrogenase isozyme 1
Therapy Area/IndicationsCognitive DysfunctionCognition DisordersDepressive Disorder, Major +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaUnited Kingdom
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesThe University Of Edinburgh
China Registration ClassN/A

Develop Information

Active CompaniesActinogen Medical Ltd
Inactive CompaniesThe University Of Edinburgh
Active IndicationsCognitive DysfunctionCognition DisordersDepressive Disorder, Major +[5] 
Inactive IndicationsCognitionSmall Fiber NeuropathyPeripheral Nervous System Diseases +[4] 

Other Information

ATC CodeN/A
Related LinksN/A